Open-Label Hepatic Impairment Study

Summary

Open-Label Hepatic Impairment Study is a clinical trial^[1].

Key Facts

• Open-Label Hepatic Impairment Study is located in Puerto Rico^[2].
• Open-Label Hepatic Impairment Study is in the country of United States^[3].
• Open-Label Hepatic Impairment Study's instance of is recorded as clinical trial^[4].
• Open-Label Hepatic Impairment Study's start time is recorded as +2011-07-31T00:00:00Z^[5].
• Open-Label Hepatic Impairment Study's end time is recorded as +2012-01-31T00:00:00Z^[6].
• Open-Label Hepatic Impairment Study's sponsor is recorded as Gilead Sciences^[7].
• Open-Label Hepatic Impairment Study's main subject is recorded as hepatitis C^[8].
• Open-Label Hepatic Impairment Study's main subject is recorded as hepatitis^[9].
• Open-Label Hepatic Impairment Study's number of participants is recorded as {'unit': '1', 'amount': '+24'}^[10].
• Open-Label Hepatic Impairment Study's title is recorded as An Open-Label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of PSI-7977 or PSI-352938 in HCV-infected Subjects With Varying Degrees of Hepatic Impairment^[11].
• Open-Label Hepatic Impairment Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[12].
• Open-Label Hepatic Impairment Study's ClinicalTrials.gov ID is recorded as NCT01497327^[13].
• Open-Label Hepatic Impairment Study's research intervention is recorded as sofosbuvir^[14].
• Open-Label Hepatic Impairment Study's clinical trial phase is recorded as phase I clinical trial^[15].
• Open-Label Hepatic Impairment Study's research subject recruitment status is recorded as completed^[16].
• Open-Label Hepatic Impairment Study's study type is recorded as interventional study^[17].